Achieving Equitable Representation in Clinical Studies

The panel has an in-depth discussion on improving diversity in clinical trials. They discuss ways to increase minority participation through community partnerships, including providing transportation, lodging, and other resources needed to enable participation.

EP: 1.Disparities in Cardiovascular Care for Diverse Populations

EP: 2.Innovation vs Access: Supporting Underserved Communities

EP: 3.Exploring Polypharmacy: Adherence, Communication, and Outcomes

EP: 4.Gender-Based Disparities in Cardiovascular Disease

EP: 5.Peripheral Arterial Disease Awareness for Minority Populations

EP: 6.Community Partnership: Increasing Public Awareness of CVD

EP: 7.Recent Data Reveals Disparities in Cardiovascular Care

EP: 8.Identifying Social Determinants of Health in Cardiovascular Care

EP: 9.Impact of Novel Medications and Out-Of-Pocket Costs in Managing Cardiovascular Disease

EP: 10.Developing Practical Solutions to Improve Cardiovascular Care

EP: 11.Advancing Cardiovascular Care Through Technological Innovation

EP: 12.Desired Technology Innovations to Prevent Cardiovascular Disease

EP: 13.Measuring Implicit Bias

Now Viewing

EP: 14.Achieving Equitable Representation in Clinical Studies

EP: 15.Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion

Related Videos

Related Content

Advertisement

November 4th 2024

Digital Intervention Reduces Early Childhood Obesity Risk in Diverse Populations

Brooke McCormick

Combining a digital intervention with health behavior counseling improved weight trajectories and lowered obesity risk in racially and ethnically diverse children over 24 months.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein

Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 1st 2024

5 Essential Drugs Currently Facing Shortages

Brooke McCormick

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of shortages lasting over 2 years due to ongoing supply and manufacturing issues.

October 31st 2024

With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer

Gayle Turim Dickstein

Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.

Related Content

Advertisement

November 4th 2024

Digital Intervention Reduces Early Childhood Obesity Risk in Diverse Populations

Brooke McCormick

Combining a digital intervention with health behavior counseling improved weight trajectories and lowered obesity risk in racially and ethnically diverse children over 24 months.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein

Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 1st 2024

5 Essential Drugs Currently Facing Shortages

Brooke McCormick

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of shortages lasting over 2 years due to ongoing supply and manufacturing issues.

October 31st 2024

With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer

Gayle Turim Dickstein

Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.